AcelRx Pharmaceuticals Inc
F:R5X
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
AcelRx Pharmaceuticals Inc
Revenue
AcelRx Pharmaceuticals Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AcelRx Pharmaceuticals Inc
F:R5X
|
Revenue
$620k
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-16%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$92.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$62.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$64.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$59.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
AcelRx Pharmaceuticals Inc
Glance View
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.
See Also
What is AcelRx Pharmaceuticals Inc's Revenue?
Revenue
620k
USD
Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Revenue amounts to 620k USD.
What is AcelRx Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
-16%
The average annual Revenue growth rates for AcelRx Pharmaceuticals Inc have been -51% over the past three years , -23% over the past five years , and -16% over the past ten years .